Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.

Livio Pagano, Luana Fianchi, Sergio Storti, Maria Teresa Voso, Caterina Giovanna Valentini, Sergio Rutella, Morena Caira, Giuseppe Leone, Franco Leoni, Giacomo Gianfaldoni

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background: Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of acute myeloid leukemia (AML). We evaluated efficacy and safety of a chemotherapy including growth factors, cytarabine, and GO (G-AraMy) in the treatment of poor-prognosis AML in elderly patients. Patients and methods: In three Italian hematology departments from September 2003 to September 2006, 53 elderly patients [median age 69 years (range 65–77)] with untreated or primary refractory/relapsed AML were enrolled on the combination G-AraMy administered according to two consecutive schedules (G-AraMy1 and G-AraMy2), with intensified consolidation in the second. Twenty-three of 53 patients had a secondary acute myeloid leukemia (sAML). Results: The overall response rate was 57%. The most common adverse event was myelosuppression. Seven patients died in induction (13%). No differences for response rate and toxicity profile were observed between untreated and primary resistant/relapsed patients, de novo AML and sAML, and in the two treatment trials. Median disease-free survival and overall survival were 8 months (range 2–23+) and 9 months (range 2–24+). Conclusions: G-AraMy therapy may be considered an useful treatment approach for poor-risk elderly AML patients, with a complete remission rate comparable to literature data with reduced side-effects, also in a poor-prognosis
Lingua originaleEnglish
pagine (da-a)128-134
Numero di pagine7
RivistaAnnals of Oncology
Stato di pubblicazionePubblicato - 2008

Keywords

  • acute mieloyd leukemia
  • elderly patients
  • gemtuzumab ozogamicin

Fingerprint Entra nei temi di ricerca di 'Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.'. Insieme formano una fingerprint unica.

Cita questo